Predict your next investment

Venture Capital
fprimecapital.com

See what CB Insights has to offer

Investments

422

Portfolio Exits

84

Funds

3

Partners & Customers

1

About F-Prime Capital

F-Prime Capital, formerly Fidelity Biosciences and Devonshire Investors, is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world's most significant challenges in healthcare and technology.

F-Prime Capital Headquarter Location

1 Main Street 13th Floor

Cambridge, Massachusetts, 02142,

United States

617-231-2400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing F-Prime Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find F-Prime Capital in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing F-Prime Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned F-Prime Capital in 6 CB Insights research briefs, most recently on Feb 16, 2021.

Latest F-Prime Capital News

Mathison Raises $25 Million To Launch the First DEI Operating System to Help Employers Make Progress on Diversity Hiring and Advancement

May 12, 2022

Mathison’s holistic DEI platform has seen 800%+ growth over the past two years May 12, 2022 11:00 AM Eastern Daylight Time NEW YORK--( BUSINESS WIRE )-- Mathison , the only solution to provide employers with an end-to-end Diversity, Equity and Inclusion (DEI) hiring and retention platform, has announced today the close of its $25 million Series A led by F-Prime Capital, with participation from Bain Capital Ventures, SemperVirens, ANIMO Ventures, GTM Fund, Gaingels and JP Morgan. The new injection of funding will be used to continue to build out our data and analytics capabilities, scale our go-to-market team and increase our collective impact with employers. As part of the round, John Lin of F-Prime Capital joins the board. This is a moment when leaders want to make real progress on diversity, but miss the insights and capabilities needed to take action. According to a study conducted by Deloitte , 69% of executives say diversity is their most important priority right now, 93% of employers lack a robust diversity hiring solution, 76% of them haven’t set diversity goals and nearly half of those who have goals are not yet confident they will achieve them. “Existing solutions are disjointed and their high price tags have made DEI cost prohibitive and operationally cumbersome to manage,” said Arthur Woods, Co-Founder of Mathison. “After leading years of research across hundreds of employers, we recognized employers were missing the proper insights and systems to support their DEI efforts at scale. We designed Mathison so employers could build a holistic DEI strategy that they could immediately mobilize into action and continuously manage across their organization.” Mathison has pioneered the first DEI Operating System to give employers a single place to manage their: DEI measurement, benchmarking and reporting Diversity sourcing to expand the hiring pipeline DEI training and tools to shift behavior and reduce bias Designed to integrate into employers’ existing systems, Mathison features DEI tools that can be implemented into every employee’s daily workflow and a comprehensive dashboard of DEI metrics for leaders. “Just as every essential business function, from payroll to sales, has had a system of record, the same should exist for DEI,” said John Lin, investor from F-Prime Capital. “Mathison is the first and only end-to-end platform for DEI, bringing together analytics and strategy into an intelligent platform that encourages employers to activate training and hiring with insights.” Mathison has made a measurable collective impact, sourcing over 50,000 underrepresented candidates for employers, supporting the development of hundreds of new equitable talent policies across over 30 industries, and engaging more than 10,000 employees in DEI training to date. “We assessed countless DEI tools and Mathison was the only real solution that enabled us to measure, source and engage the team all at once,” said Kathy Schrepferman, a talent leader from Cornerstone OnDemand. “We feel grateful to have founded Mathison with the intentional mission of making DEI a possibility for organizations through transparency, measurement and accountability. Our community and movements have galvanized around our efforts to strive for more,” said Dave Walsh, CEO and Co-Founder of Mathison. “Our system is designed to instill real meaningful change and we are excited to use this funding to propel the DEI efforts of thousands of organizations to create a more equitable future”. Mathison uses its own product for DEI and includes 50% women, 72% working parents and 50% people of color on its management team. To learn more about Mathison, please visit www.mathison.io About Mathison Mathison is the world’s first DEI Operating System. Its end-to-end platform transforms organizations’ hiring and retention strategies to increase diversity with a single place to build their DEI action plan, measure growth and mobilize every team with education and tools. A leader in DEI innovation and research, their book, Hiring for Diversity, was named a bestseller and is referenced by organizations across the globe. Mathison works with a wide range of employers of all sizes including companies like Sonos, TripAdvisor, 23andMe, HelloFresh, Bowery Farms, Bristol Myers Squibb and non-profits from Sundance Film to The World Economic Forum. For more information, please visit: www.mathison.io . About F-Prime Capital: F-Prime Capital is a global venture capital firm investing in healthcare and technology. For the past 50 years, our independent venture capital group has had the privilege of backing great entrepreneurs building groundbreaking companies. With over two billion dollars under management and a global portfolio of more than 160 companies, we champion those dedicated to creating positive change in the world. In healthcare, we focus on therapeutics, medtech, and health IT & services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech; while we're early-stage investors by choice, we'll back exceptional teams at any stage. Our team of investors, engineers, doctors, and scientists is committed to bringing the insight, domain expertise, and relationships required to help our companies make a transformational impact. F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com and follow us on Twitter and LinkedIn. Contacts

F-Prime Capital Investments

422 Investments

F-Prime Capital has made 422 investments. Their latest investment was in Mathison as part of their Series A on May 5, 2022.

CBI Logo

F-Prime Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/12/2022

Series A

Mathison

$25M

Yes

3

4/11/2022

Series B

Invetx

$60.5M

Yes

2

4/5/2022

Series A

Eleos Health

$20M

Yes

4

3/30/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/28/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/12/2022

4/11/2022

4/5/2022

3/30/2022

3/28/2022

Round

Series A

Series B

Series A

Series A

Series A

Company

Mathison

Invetx

Eleos Health

Subscribe to see more

Subscribe to see more

Amount

$25M

$60.5M

$20M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

2

4

10

10

F-Prime Capital Portfolio Exits

84 Portfolio Exits

F-Prime Capital has 84 portfolio exits. Their latest portfolio exit was Ivenix on March 31, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/31/2022

Acquired

$99M

6

1/11/2022

Acq - Talent

2

1/6/2022

Acquired

2

12/16/2021

Acquired

Subscribe to see more

Subscribe to see more

10

12/10/2021

IPO

Subscribe to see more

Subscribe to see more

10

Date

3/31/2022

1/11/2022

1/6/2022

12/16/2021

12/10/2021

Exit

Acquired

Acq - Talent

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

2

2

10

10

F-Prime Capital Acquisitions

1 Acquisition

F-Prime Capital acquired 1 company. Their latest acquisition was Citrine Medicine on January 01, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/1/2019

Series A

$99M

$80M

Acq - Fin

1

Date

1/1/2019

Investment Stage

Series A

Companies

Valuation

$99M

Total Funding

$80M

Note

Acq - Fin

Sources

1

F-Prime Capital Fund History

3 Fund Histories

F-Prime Capital has 3 funds, including Fidelity Biosciences.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Fidelity Biosciences

Early-Stage Venture Capital

Closed

1

Fidelity Biosciences Fund II

Subscribe to see more

Subscribe to see more

10

Beacon Bioventures Fund III LP

Subscribe to see more

Subscribe to see more

10

Closing Date

Fund

Fidelity Biosciences

Fidelity Biosciences Fund II

Beacon Bioventures Fund III LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

Sources

1

10

10

F-Prime Capital Partners & Customers

1 Partners and customers

F-Prime Capital has 1 strategic partners and customers. F-Prime Capital recently partnered with Atlas on October 10, 2014.

Date

Type

Business Partner

Country

News Snippet

Sources

10/21/2014

Partner

United States

Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner

As the promise of harnessing the immune system to fight cancer grabs headlines around the industry , venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics , a Cambridge , MA , startup with a hybrid approach to the field .

1

Date

10/21/2014

Type

Partner

Business Partner

Country

United States

News Snippet

Meet Unum, a new immunotherapy biotech with Fidelity, Atlas and Sanofi in its corner

As the promise of harnessing the immune system to fight cancer grabs headlines around the industry , venture stalwarts Fidelity Biosciences and Atlas Venture have teamed up to launch Unum Therapeutics , a Cambridge , MA , startup with a hybrid approach to the field .

Sources

1

F-Prime Capital Team

7 Team Members

F-Prime Capital has 7 team members, including current President, Chief Operating Officer, Thomas Beck.

Name

Work History

Title

Status

Thomas Beck

President, Chief Operating Officer

Current

Stephen Knight

President, Managing Partner

Current

Mary Bevelock Pendergast

Globespan Capital Partners, and Pretzel Logic Software

Chief Financial Officer

Current

Shervin Ghaemmaghami

Senior Vice President

Current

David Jegen

Managing Partner

Current

Name

Thomas Beck

Stephen Knight

Mary Bevelock Pendergast

Shervin Ghaemmaghami

David Jegen

Work History

Globespan Capital Partners, and Pretzel Logic Software

Title

President, Chief Operating Officer

President, Managing Partner

Chief Financial Officer

Senior Vice President

Managing Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.